Ferrous Ascorbate 30mg +Folic acid 500mcg + Zinc Sulphate - 22.5 mg
Ferrous Ascorbate 30mg + Folic acid 500 mg + Zinc sulphate 22.5 mg.
The Indian pharmaceutical market is expanding at a good pace and poses good prospects to the pharma distributors and entrepreneurs. IRONEW (Drug), which is a formulation containing Ferrous Ascorbate, Folic Acid and Zinc Sulphate is a popular formulation in the nutraceutical and mineral supplement market.
With the growing demand of the nutrition supplement formulations, which includes iron, a number of pharma professionals and distributors would want to invest in the IRONEW (Drug) PCD Pharma Franchise in India. This franchise business will enable the entrepreneurs and the medical representatives to diversify their portfolio of pharmaceutical products to one with a high demand in the market.
Ferrous Ascorbate, Folic Acid and Zinc compound formulations are generally sold in pharmacies, hospitals and health care supply chains. The pharmaceutical industry in the nutritional supplement segment still continues to expand steadily, generating demand to the nutritional supplement formulations.
Due to this growing need, the IRONEW (Drug) PCD Franchise is an attractive business venture to any pharma distributor that would opt to create a solid market presence within the nutraceutical product division.
Pharmaceutical companies that have the IRONEW (Drug) PCD Pharma Franchise normally offer a good business support to their franchisee.
Key benefits may include:
With such benefits, franchise partners develop an effective distribution network and grow their pharmaceutical business.
A majority of pharmaceutical companies make IRONEW (Drug) in GMF-approved manufacturing plants, but they also observe high quality control. Pharmaceutical market is characterized by high standards of manufacturing which guarantee consistency and reliability of the products.
Insisting on high production level assists the franchise partners in promoting the product without fear and develop confidence with the distributors and retailers.
IRONEW (Drug) PCD Franchise represents a great chance to pharma distributors and entrepreneurs who would like to expand their pharmaceutical business into the nutraceutural and mineral supplement segment.
The IRONEW (Drug) PCD Pharma Franchise has potential to build a stable and profitable pharmaceutical distribution network because of the high market demands, consistent manufacturing standards, and extensive franchise support.
Certified Products
PAYMENTS
Customer Support
Ferrous Ascorbate 30mg + Folic acid 500 mg + Zinc sulphate 22.5 mg.
The Indian pharmaceutical market is expanding at a good pace and poses good prospects to the pharma distributors and entrepreneurs. IRONEW (Drug), which is a formulation containing Ferrous Ascorbate, Folic Acid and Zinc Sulphate is a popular formulation in the nutraceutical and mineral supplement market.
With the growing demand of the nutrition supplement formulations, which includes iron, a number of pharma professionals and distributors would want to invest in the IRONEW (Drug) PCD Pharma Franchise in India. This franchise business will enable the entrepreneurs and the medical representatives to diversify their portfolio of pharmaceutical products to one with a high demand in the market.
Ferrous Ascorbate, Folic Acid and Zinc compound formulations are generally sold in pharmacies, hospitals and health care supply chains. The pharmaceutical industry in the nutritional supplement segment still continues to expand steadily, generating demand to the nutritional supplement formulations.
Due to this growing need, the IRONEW (Drug) PCD Franchise is an attractive business venture to any pharma distributor that would opt to create a solid market presence within the nutraceutical product division.
Pharmaceutical companies that have the IRONEW (Drug) PCD Pharma Franchise normally offer a good business support to their franchisee.
Key benefits may include:
With such benefits, franchise partners develop an effective distribution network and grow their pharmaceutical business.
A majority of pharmaceutical companies make IRONEW (Drug) in GMF-approved manufacturing plants, but they also observe high quality control. Pharmaceutical market is characterized by high standards of manufacturing which guarantee consistency and reliability of the products.
Insisting on high production level assists the franchise partners in promoting the product without fear and develop confidence with the distributors and retailers.
IRONEW (Drug) PCD Franchise represents a great chance to pharma distributors and entrepreneurs who would like to expand their pharmaceutical business into the nutraceutural and mineral supplement segment.
The IRONEW (Drug) PCD Pharma Franchise has potential to build a stable and profitable pharmaceutical distribution network because of the high market demands, consistent manufacturing standards, and extensive franchise support.
FAQ
